Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACUVAIL vs ALCAFTADINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis by blocking cyclooxygenase (COX-1 and COX-2) enzymes. This reduces ocular inflammation and pain.
Selective histamine H1 receptor antagonist; inhibits histamine release from mast cells and reduces ocular itch associated with allergic conjunctivitis.
Reduction of ocular pain and inflammation following cataract surgery,Treatment of ocular itching associated with seasonal allergic conjunctivitis
FDA: Prevention of itching associated with allergic conjunctivitis,Off-label: No established off-label uses
1 drop in the affected eye 4 times daily.
1 drop of 0.25% ophthalmic solution in each affected eye twice daily.
Terminal elimination half-life is approximately 46 minutes in the aqueous humor following ocular administration in humans.
Terminal elimination half-life is approximately 2 hours (range 1.5–3 h) after topical ocular administration, appropriate for twice-daily dosing.
Primarily hepatic via conjugation with glucuronic acid; minor role of cytochrome P450 enzymes. Approximately 50% is excreted as parent drug and metabolites in urine.
Not extensively metabolized; primarily excreted unchanged in urine. Cytochrome P450 metabolism is minimal.
Primarily renal excretion of metabolites; less than 1% excreted unchanged. Biliary/fecal elimination accounts for <10%.
Primarily renal (approximately 50% unchanged), with the remainder as metabolites; negligible biliary/fecal elimination.
>99% bound to plasma proteins, primarily albumin.
Approximately 40% bound to plasma proteins.
Intravenous administration in animals suggests Vd ~0.15 L/kg, indicating limited distribution; clinically, it distributes into aqueous humor after topical dosing.
Vd is approximately 1.4 L/kg, indicating distribution beyond plasma into extravascular tissues.
Ocular bioavailability is dependent on formulation; systemic bioavailability after topical ocular administration is extremely low (<1%).
Systemic bioavailability after topical ocular administration is low (estimated < 0.5%) due to dilution, local metabolism, and limited corneal penetration.
No adjustment required. Drug is minimally systemically absorbed.
No dose adjustment required for any degree of renal impairment.
No adjustment required. Drug is minimally systemically absorbed.
No dose adjustment required for any degree of hepatic impairment.
Safety and efficacy in pediatric patients have not been established.
Children 2 years and older: same as adult dose. Safety and efficacy in children under 2 years not established.
No specific dosage adjustment is recommended; use same dose as younger adults.
No specific dose adjustment needed; use same dose as for younger adults.
No black box warning for ophthalmic use; however, systemic NSAIDs carry risk of serious cardiovascular and gastrointestinal events. Ophthalmic use rarely associated with corneal adverse events.
None
Use with caution in patients with bleeding disorders or those on anticoagulants; may prolong bleeding time. Avoid in patients with known hypersensitivities to NSAIDs or aspirin. Can cause corneal keratopathy; discontinue if corneal epithelial breakdown occurs.
Do not inject; for topical ophthalmic use only,Avoid wearing contact lenses if eyes are red,May cause temporary blurred vision after instillation,Use with caution in patients with known hypersensitivity
Hypersensitivity to any component of the formulation. Active corneal epithelial defect. Patients with aspirin-sensitive asthma.
Hypersensitivity to alcaftadine or any component of the formulation
No specific food interactions; systemic absorption is minimal with ophthalmic use. Avoid concurrent use of other NSAID eye drops due to additive irritation.
No specific food interactions reported. As an ophthalmic preparation, systemic absorption is minimal and unlikely to be affected by food.
Acuvail (ketorolac tromethamine ophthalmic solution) is classified as FDA Pregnancy Category C. Systemic exposure after ocular administration is minimal; however, NSAIDs may cause premature closure of the ductus arteriosus and oligohydramnios in the third trimester. Use during the first and second trimesters should be limited to cases where potential benefit outweighs risk; avoid during the third trimester due to risk of fetal harm.
Alcaftadine is classified as Pregnancy Category B. Animal studies have not demonstrated teratogenic effects at doses up to 2400 times the human ocular dose. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, alcaftadine should be used during pregnancy only if clearly needed.
Ketorolac is excreted in human milk following systemic administration, but ocular doses produce negligible systemic levels. The M/P ratio is not determined for ophthalmic use. Use with caution in nursing mothers, as the clinical significance is likely low due to minimal systemic absorption.
It is not known whether alcaftadine is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when alcaftadine is administered to a nursing woman. The M/P ratio has not been established.
No dosage adjustment is required for ophthalmic use during pregnancy, as systemic exposure is negligible. However, avoid use in third trimester due to risks. Pharmacokinetic changes in pregnancy do not significantly alter ocular delivery.
No pharmacokinetic studies have been performed in pregnant women. Based on the available animal data and the low systemic exposure after ocular administration, no dosing adjustment is recommended during pregnancy.
Acuvail (ketorolac tromethamine ophthalmic solution 0.45%) is a nonsteroidal anti-inflammatory drug (NSAID) for ocular use. It is preserved with sodium chloride and not benzalkonium chloride, reducing corneal epithelial toxicity. Administer 1 drop twice daily for ocular pain and inflammation following cataract surgery. Use caution in patients with bleeding tendencies or those on anticoagulants due to risk of increased ocular bleeding. Monitor for corneal epithelial defects and keratitis, especially with prolonged use.
ALCAFTADINE is a topical ophthalmic antihistamine and mast cell stabilizer used for allergic conjunctivitis. Administer one drop twice daily in each affected eye. Onset of action is within minutes. Contraindicated in patients with hypersensitivity to any component. Use with caution in contact lens wearers; remove lenses before instillation and wait 10 minutes before reinserting. Do not touch dropper tip to any surface to avoid contamination.
Wash hands before each use; do not touch tip of bottle to eye or any surface to avoid contamination.,Remove contact lenses before instillation and wait at least 15 minutes before reinserting.,Contact your doctor if you experience eye pain, redness, vision changes, or if symptoms worsen.,Do not use this medication while wearing contact lenses unless directed by your doctor.,Store at room temperature, keep bottle tightly closed when not in use, and discard within 28 days of opening.
Do not wear contact lenses if your eyes are red; after the redness subsides, wait at least 10 minutes after instilling the drop before reinserting lenses.,Do not touch the dropper tip to your eye or any surface to avoid contamination.,Wait at least 5 minutes between using this drug and other eye drops.,If you miss a dose, use it as soon as you remember; if it is almost time for the next dose, skip the missed dose and resume your regular schedule.,Do not use more than prescribed; overuse may cause eye irritation.,Tell your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Wash hands before and after use.
No interactions on record
"Dextroamphetamine, a central nervous system stimulant, may reduce the sedative effects of Alcaftadine, an antihistamine used for allergic conjunctivitis, by opposing its central histamine H1 receptor blockade. This pharmacodynamic antagonism can lead to diminished sedation and potentially decreased therapeutic efficacy of Alcaftadine for its intended ocular antiallergic effects. Patients may experience reduced symptom relief and increased ocular discomfort."
"Hydroxyamphetamine may decrease the sedative activities of Alcaftadine."
"Phentermine may decrease the sedative activities of Alcaftadine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACUVAIL vs ALCAFTADINE, answered by our medical review team.
ACUVAIL is a NSAID Ophthalmic that works by Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis by blocking cyclooxygenase (COX-1 and COX-2) enzymes. This reduces ocular inflammation and pain.. ALCAFTADINE is a Ophthalmic Antihistamine that works by Selective histamine H1 receptor antagonist; inhibits histamine release from mast cells and reduces ocular itch associated with allergic conjunctivitis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACUVAIL and ALCAFTADINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACUVAIL is: 1 drop in the affected eye 4 times daily.. The standard adult dose of ALCAFTADINE is: 1 drop of 0.25% ophthalmic solution in each affected eye twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACUVAIL and ALCAFTADINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACUVAIL is classified as Category C. Acuvail (ketorolac tromethamine ophthalmic solution) is classified as FDA Pregnancy Category C. Systemic exposure after ocular administration is minimal; however, NSAIDs may cause . ALCAFTADINE is classified as Category C. Alcaftadine is classified as Pregnancy Category B. Animal studies have not demonstrated teratogenic effects at doses up to 2400 times the human ocular dose. There are no adequate a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.